We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
+45.62%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$414M
AUM Growth
+$229M
Cap. Flow
+$126M
Cap. Flow %
30.53%
Top 10 Hldgs %
96.3%
Holding
19
New
5
Increased
1
Reduced
4
Closed
4

Top Buys

Rank Stock Value
1
APTX
Aptinyx Inc. Common Stock
APTX
+$70.4M
2
STIM icon
Neuronetics
STIM
+$42M
3
ITRM
Iterum Therapeutics
ITRM
+$17.5M
4
COGT icon
Cogent Biosciences
COGT
+$15M
5
TECX
Tectonic Therapeutic
TECX
+$4.51M

Top Sells

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$8.6M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$7.31M
3
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$3.77M
4
TRIL
Trillium Therapeutics Inc.
TRIL
+$2.91M
5
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$1.33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCPH
1
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$161M 38.98%
4,104,140
– –
APTX
2
DELISTED
Aptinyx Inc. Common Stock
APTX
$79.5M 19.19%
+3,290,079
New +$70.4M
STIM icon
3
Neuronetics
STIM
$123M
$41.1M 9.91%
+1,543,115
New +$42M
CRSP icon
4
CRISPR Therapeutics
CRSP
$4.61B
$26.1M 6.31%
444,708
-150,934
-25% -$8.6M
COGT icon
5
Cogent Biosciences
COGT
$6.76B
$25.8M 6.22%
448,886
+311,386
+226% +$15M
WVE icon
6
Wave Life Sciences
WVE
$1.12B
$16.6M 4%
433,429
-24,830
-5% -$1.07M
ITRM
7
DELISTED
Iterum Therapeutics
ITRM
$15.5M 3.75%
+97,087
New +$17.5M
SRRA
8
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$14.9M 3.59%
125,511
– –
OBSV
9
DELISTED
ObsEva SA Ordinary Shares
OBSV
$13.5M 3.25%
890,501
– –
ARAV
10
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.55M 1.1%
+374,500
New +$3.86M
TECX
11
Tectonic Therapeutic
TECX
$576M
$4.28M 1.03%
+12,500
New +$4.51M
OXFD
12
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$4.02M 0.97%
311,660
-540,837
-63% -$7.31M
AFMD
13
DELISTED
Affimed
AFMD
$3.71M 0.9%
225,000
– –
PDSB icon
14
PDS Biotechnology
PDSB
$38.4M
$2.42M 0.58%
117,243
– –
AVEO
15
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$909K 0.22%
40,212
-56,240
-58% -$1.33M
MRNS
16
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-85,638
Closed -$1.31M
TRIL
17
DELISTED
Trillium Therapeutics Inc.
TRIL
– –
-404,159
Closed -$2.91M
DERM
18
DELISTED
Dermira, Inc.
DERM
– –
-61,109
Closed -$488K
RSLS
19
DELISTED
ReShape Lifesciences Inc. Common Stock
RSLS
– –
-1,239
Closed -$3.77M

Similar funds

BAM
Broadcrest Asset Management Winter Park, Florida $44.1M AUM 4.51% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
WCPI
Wynnchurch Capital Partners IV Rosemont, Illinois $44.8M AUM 11.91% 1-Year Est. Return
WAMC
Western Asset Management Company Pasadena, California $45.2M AUM 6.96% 1-Year Est. Return
CC
Corton Capital Carrying Place, Ontario, Canada $40.7M AUM 52.32% 1-Year Est. Return
CIEP
Constellation Investimentos e Participacoes Sao Paulo, Brazil $46.7M AUM 23.3% 1-Year Est. Return
IPI
Inflection Point Investments London, United Kingdom $46.9M AUM 18.35% 1-Year Est. Return
VSAM
Value Star Asset Management Hong Kong $49.2M AUM 60.1% 1-Year Est. Return

New Leaf Venture Partners's Q2 2018 Portfolio in Review

As of Q2 2018, New Leaf Venture Partners held 19 positions worth $414M, up 124% from $185M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

New Leaf Venture Partners deployed $126M of net new capital in Q2 2018, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Aptinyx Inc. Common Stock: 3,290,079 shares worth $79.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

On the sell side, the largest reduction was CRISPR Therapeutics, an estimated $8.6M trimmed.

  • New Leaf Venture Partners's largest Q2 2018 buy was Aptinyx Inc. Common Stock: 3,290,079 shares worth $79.5M.
  • New Leaf Venture Partners added most to Cogent Biosciences in Q2 2018, an estimated $15M increase.
  • New Leaf Venture Partners's biggest Q2 2018 reduction was CRISPR Therapeutics, cutting an estimated $8.6M.
  • New Leaf Venture Partners fully exited ReShape Lifesciences Inc. Common Stock in Q2 2018, selling an estimated $3.77M.
  • New Leaf Venture Partners's ten largest holdings make up 96% of its $414M portfolio in Q2 2018.
  • New Leaf Venture Partners opened 5 new positions and closed 4 in Q2 2018.
  • New Leaf Venture Partners's portfolio value rose 124% quarter-over-quarter to $414M.

Based on New Leaf Venture Partners's 13F filing for Q2 2018, filed 14 Aug 2018.